Repligen
RGEN
Repligen (RGEN) - Total debt
Total debt on the balance sheet as of March 2024 : $0.73 B
According to Repligen 's latest financial reports the company's total debt is $0.73 B. A company’s total debt is the sum of all current and non-current debts.
Repligen - Total debt on balance sheet (from 2004 to 2024)
Total debt by year
| Year | Total debt | Change |
|---|---|---|
| 2023-12-31 | $0.71 B | 68.29% |
| 2022-12-31 | $0.42 B | 15.55% |
| 2021-12-31 | $0.36 B | 32.91% |
| 2020-12-31 | $0.27 B | 4.59% |
| 2019-12-31 | $0.26 B | 154.44% |
| 2018-12-31 | $0.10 B | 4.27% |
| 2017-12-31 | $99.25 M | 4.18% |
| 2016-12-31 | $95.27 M | |
| 2005-03-31 | $0.11 M | 40% |
| 2004-03-31 | $0.08 M |
Total debt for similar companies or competitors
| Company | Total debt | differencediff. | Country |
|---|---|---|---|
 Pfizer PFE | $70.84 B | 9,503.11% | 🇺🇸 USA |
 Thermo Fisher Scientific TMO | $34.91 B | 4,633.03% | 🇺🇸 USA |
 General Electric GE | $20.52 B | 2,682.18% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | $57.40 B | 7,681.84% | 🇺🇸 USA |
 Sangamo Therapeutics
SGMO | $38.1 M | -94.83% | 🇺🇸 USA |
 Novavax NVAX | $0.22 B | -68.95% | 🇺🇸 USA |
 Neurocrine Biosciences
NBIX | $0.51 B | -30.61% | 🇺🇸 USA |
 Bio-Techne TECH | $0.55 B | -24.67% | 🇺🇸 USA |
 BioMarin Pharmaceutical BMRN | $1.09 B | 48.64% | 🇺🇸 USA |
 Charles River Laboratories
CRL | $3.06 B | 315.65% | 🇺🇸 USA |